Abbvie phase III miss with veliparib puts wrinkle in PARP effort
Veliparib, Abbvie Inc.'s only shot at the oral poly-ADP ribose polymerase (PARP) market, failed two key phase III tests, missing the primary endpoints in studies evaluating the agent in combination with carboplatin and paclitaxel in patients with squamous non-small-cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST